Skip to content

Effect of Somatostatin on the Prevention from Pancreatitis and Quality of life of the patients post-ERCP: A randomized controlled trial

Effect of Somatostatin on the Prevention from Pancreatitis and Quality of life of the patients post-ERCP: A randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021583
Enrollment
Unknown
Registered
2019-02-28
Start date
2019-02-27
Completion date
Unknown
Last updated
2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Interventions

1:Somatostatin
2:Placebo

Sponsors

Jiangxi Pingxiang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Including common bile duct stones, malignant biliary stricture, benign biliary stricture, chronic pancreatitis, SOD, unknown causes, patients with no signs of infection before surgery, no antibiotics, tumor patients did not give chemotherapy drugs. Two groups of patients were divided into postoperative high-risk PEP group (age 42.5±24.1 years) and postoperative PEP low-risk group (age 44.6±26.2 years). Diagnostic criteria for high-risk group: (1) difficult intubation (intubation time greater than 15 min or = 10 intubation unsuccessful); (2) guide wire repeatedly into the pancreatic duct (= 3 times); (3) guide wire pancreatic duct Occupation method, assisted bile duct intubation; (4) transthoracic sphincter incision; (5) large bile duct stones (= 2 cm), further stone removal after gravel removal; (6) contrast agent leads to pancreatic duct development; (7) sphincter dysfunction; (8) endoscopic sphincterotomy (EST)

Exclusion criteria

Exclusion criteria: (1) Previous EST patients; (2) Patients with acute pancreatitis 2 weeks before surgery; (3) Preoperative serum amylase abnormalities or imaging examinations suggest abnormal pancreas; (4) Patients with signs of infection before surgery.

Design outcomes

Primary

MeasureTime frame
Blood amylase;

Secondary

MeasureTime frame
Ratio of pancreatitis;

Countries

China

Contacts

Public ContactWang Guiliang

Jiangxi Pingxiang People's Hospital

guiliangwang@126.com+86 0799 6881797

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026